Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations
SEATTLE–(BUSINESS WIRE)–Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, today announced the successful close of its most recent round of funding led by BioLife Solutions, the global…
